EU H2020 Project "DOSIKIT (DosiKit, a first portable field medical device for fast triage of people..)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/224634/index.html
-1	/open-h2020/projects/213950/index.html
-2	/open-consip/fornitori/2018/profilo-01472930518/index.html
-3	/open-h2020/per-topic/loader/list/index.html

DosiKit project word cloud

Explore the words cloud of the DosiKit project. It provides you a very rough idea of what is the project "DosiKit" about.

care french radiological specialist exercise emergency published biodosimetry acubens armies nuclear hospitals energy commercial fto requiring minutes competencies business responders actions invented forecasted final unmet experimented transportable usa sales founded international doctors individuals protected expose loi medical critical game pbi risk 2014 schedule 15 exposure exposed 2022 uniting managers dosimetric survey crisis dosikit validated cartography nrbc partial oral communications innovative regulatory continued biological young prototype sme seasoned staff changer trl6 diagnostic instrument team 2024 irradiated bio atomic army performed validation technological germany singapore patents starting 2009 commercialize initiated fast triage israel irradiation ip device market publications lack revenue tools people reached accident 45 radiation potentially giving scientific fulfil classify body undergoing worldwide collaborations initial contact booster

Project "DosiKit" data sheet

The following table provides information about the project.

Coordinator	ACUBENS Organization address address: 15 RUE PIERRE GILLES DE GENNES city: NANTERRE postcode: 92160 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2019
Duration (year-month-day)	from 2019-08-01 to 2020-01-31

#	participants	country	role	EC contrib. [€]
1	ACUBENS	FR (NANTERRE)	coordinator	50˙000.00

ACUBENS

FR (NANTERRE)

coordinator

50˙000.00

Project objective

Acubens was founded in 2014, to develop and commercialize new game-changer medical diagnostic devices around NRBC emergency. Our team gathers young and experimented doctors, and seasoned business managers, uniting their competencies to develop nuclear/radiological/biological innovative transportable biodosimetry devices. Nuclear/radiological accident can expose individuals to radiation, with the need for fast triage of potentially exposed people requiring immediate medical care. There is today a lack of irradiation biodosimetry tools that can be used in the field, by non-specialist staff, giving immediate results and exposure cartography in case of Partial-Body irradiation (PBI). To fulfil this critical unmet need for better initial crisis management, we invented the DosiKit device and fast test (45 minutes) to identify and classify irradiated individuals, directly in the field. This development was initiated in 2009 by the French Atomic Energy Commission within the European Commission program, BOOSTER (‘BiO-dOSimetric Tools for triagE to Responders’), and then continued by Acubens. DosiKit technology is protected by 3 international patents and has reached TRL6 with a prototype validated in a large-scale exercise performed with the French army. Several collaborations are undergoing for biological validation with French research institute and hospitals. Scientific and technical development was published in 3 scientific publications and many international oral communications. A strong contact has established with French, Germany, Israel, US and Singapore armies (LoI). This DosiKit product will be on the market in 2022, starting in Europe and then extending worldwide. Forecasted sales revenue is 15 M€ in 2024. The objectives of this phase 1 SME-Instrument are: (1) the final Biological and Technological validation of the device, (2) IP, FTO, Regulatory and risk assessment studies and (3) a market survey in Europe and USA to schedule our commercial actions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DOSIKIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DOSIKIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)